Kuria's CEO to Attend Upcoming J.P. Morgan Healthcare Conference

Kuria Therapeutics, a pharmaceutical company developing a platform of novel NRF2 activators for ophthalmic disease, will be holding meetings with investors and other parties during the 44th Annual J.P. Morgan Healthcare Conference, January 11-15 2026, in San Francisco, California.

Kuria's Chief Executive Officer, Dr. Keith Ward, will be holding one-on-one meetings during the conference to discuss the latest company and data updates for Kuria's lead program transforming treatment of Fuchs' dystrophy.

During the conference, Kuria will participate in both RESI 2026 (Redefining Every Stage of Investment from Seed to Exit) and BIO Partnering @ JPM 2026. 1:1 meetings can be requested through either of those platforms for participants; for other scheduling requests, email KuriaJPM@kuriatx.com.

About Kuria Therapeutics, Inc.: Kuria Therapeutics is redefining treatment for Fuchs’ dystrophy, a progressive corneal disease currently addressed only by invasive surgery in end-stage patients. Kuria's lead asset is a first-in-class NRF2 activator eye drop that addresses the root cause of Fuchs’, offering the potential for a disease-modifying therapy that improves visual acuity and reverses progression in a >$5B market. Beyond Fuchs’, Kuria’s pipeline of locally delivered NRF2 activators spans radiation dermatitis, cataract surgery, and glaucoma neuroprotection. For more information, visit www.kuriatx.com.

Contacts

Investor Relations and Media Kuria Therapeutics: Corporate Communication info@kuriatx.com